Immunocore Holdings plc (IMCR) stock
Close on Nov 12, 2026Market cap $1.57BP/E –Yield 0.00%
Immunocore Holdings plc grew revenue 13.1% to $429.30M over the twelve months to Sep 30, 2026. Free cash flow was -$18.21M, down 717.5% from a year earlier. At the latest close the market valued the company at $1.57B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.57B
- P/E ratio
- –
- Price to sales
- 3.66
- Price to book
- 3.74
- Dividend yield
- 0.00%
- Free cash flow yield
- -1.16%
Fundamentals
- Revenue
- $429.30M
- Net income
- -$32.12M
- EPS, diluted
- -$0.64
- Free cash flow
- -$18.21M
- Book value per share
- $8.14
- Diluted shares
- 52M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $31.65
- Open
- $31.65
- Day's range
- $30.08 – $31.65
- Volume
- 460,992
- Average volume (20 days)
- 568,444
- Beta (5 years)
- 0.70
- 52-week range
- $27.50 – $40.71
- RSI (14 days)
- 48.0
- Volatility (1 year)
- 37.5%
- Relative volume
- 0.97×
- WACC
- 8.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMCR | S&P 500 | Difference | IMCR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.9% | -2.7% | +7.6 pts | ||
| 3 months | -12.3% | -1.7% | −10.5 pts | ||
| Year to date | -12.2% | +11.9% | −24.1 pts | ||
| 1 year | -13.6% | +12.0% | −25.6 pts | ||
| 3 years | -39.3% | +78.2% | −117.5 pts | -15.3% | +21.2% |
| 5 years | -23.0% | +73.2% | −96.3 pts | -5.1% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immunocore filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Immunocore
Biological Products, (No Diagnostic Substances)
The company is a commercial-stage biotechnology firm that discovers and develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases. Using its proprietary off-the-shelf ImmTAX platform, which combines engineered soluble T-cell receptor targeting systems with tailored immune-modulating effectors, it advances therapies across oncology, viral infections, and autoimmune indications. Its lead commercial product, KIMMTRAK, treats adult patients with unresectable or metastatic uveal melanoma. Its customer base includes cancer patients, health systems, and healthcare providers, supported by commercial third-party payors, commercial insurers, managed healthcare organizations, and government health programs.
Company profile, executives and historyImmunocore stock: common questions
What is Immunocore's stock price?
IMCR closed at $30.48 on Nov 12, 2026, down 3.71% on the day. Over the past 52 weeks it traded between $27.50 and $40.71.
What is Immunocore's market cap?
Immunocore was worth $1.57B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IMCR's P/E ratio?
Immunocore lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.64), so it has no meaningful P/E ratio.
How much revenue does Immunocore make?
Immunocore reported revenue of $429.30M for the twelve months to Sep 30, 2026, up 13.1% from a year earlier.
Does Immunocore pay a dividend?
No. Immunocore has not paid a cash dividend over the last twelve months.
When does Immunocore report earnings next?
Immunocore is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IMCR stock performed over the past year?
Including dividends, IMCR returned -13.6% over the past year, against +12.0% for the S&P 500.
Who are Immunocore's competitors?
Companies most similar to Immunocore by business, industry and size include IOVA, IBRX, ALVO, VIR, AUTL.
See a number that looks wrong?